TRACON Pharmaceuticals

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.

TRACON Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical Device sector. The company focuses on Biotechnology and has secured $13.6B in funding across 120 round(s). With a team of 11-50 employees, TRACON Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - TRACON Pharmaceuticals, raised $14.0M. Discover more about their projects, partnerships, and impact on our platform.